MichaelSGordonMD
Oncology • Scottsdale, AZGenitourinary Oncology, Gynecologic Cancer, Hematologic Oncology, Melanoma
Chief Medical Officer at HonorHealth Research Institute Medical Director, Oncology Clinical Trials at HonorHealth Research Institute
Dr. Gordon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10510 N 92nd Street Suite 200
Scottsdale, AZ 85258Phone+1 480-323-1350
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
University of ChicagoResidency, Internal Medicine, 1985 - 1988
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1985
Sophie Davis School for Biomedical Education at CCNYBS, Biomedical Science, 1979 - 1983
Certifications & Licensure
AZ State Medical License 2000 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema
- Safety and Efficacy Study of Glufosfamide in Ovarian Cancer Start of enrollment: 2007 Jan 01
- Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors Start of enrollment: 2008 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 404 citationsActivity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante, Michael S. Gordon, Nicholas J. Vogelzang
The Lancet. Oncology. 2012-08-01 - 3938 citationsPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsRoy S. Herbst, Jean-Charles Soria, Marcin Kowanetz, Gregg Fine, Omid Hamid
Nature. 2014-11-27 - 15 citationsA phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumorsMonica M. Mita, Michael S. Gordon, Narmyn Rejeb, Athos Gianella-Borradori, V. Jego
Targeted Oncology. 2014-09-01
Journal Articles
- Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaBeth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, Christopher A Yasenchak, Michael S Gordon, Primo Lara, Clinical Lung Cancer
- E6201, an Intravenous MEK1 Inhibitor, Achieves an Exceptional Response in BRAF V600E-Mutated Metastatic Malignant Melanoma with Brain MetastasesMitesh J Borad, Raoul Tibes, Michael S Gordon, Ronald L Korn, Investigational New Drugs
Authored Content
- Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaOctober 2018
Press Mentions
TGen Partners with a Phoenix-Area Hospital System to Test COVID-19 TreatmentMay 5th, 2020
Advances in Cancer TreatmentSeptember 29th, 2017
Arizona Cancer Center Faces Crowded Cancer-Care MarketSeptember 2nd, 2015
Professional Memberships
- Member
- Member
Industry Relationships
- co-Founder, Caremission
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
